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Abstract Screening of a phage library displaying single chain 
fragments of the variable regions of human immunoglobulins 
(scFv) for binding to the ovarian chicken very low-density 
lipoprotein/viteHogenin receptor (OVR) led to the isolation of 
several antibody fragments with high affinity. As for the natural 
ligands of OVR, receptor binding of all antibody fragments is 
strictly Ca2+-dependent and is prevented by receptor-associated 
protein (RAP). Moreover, attachment of human rhinovirus 
serotype 2 (HRV2) to this receptor is inhibited by aH scFvs. In 
contrast to conventional immunization, the in vitro selection 
method thus exclusively led to antibodies that attach to or close 
to the ligand binding site and thereby block the receptor-ligand 
interaction. 
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1. Introduction 
Polypeptides of the low-density lipoprotein receptor 
(LDLR) family are remarkably related; their common struc- 
tural motives are clusters of variable numbers of cysteine rich 
'binding repeats' of about 40 amino acids in length. Whereas 
LDLR contains 7 such repeats, the very low-density lipopro- 
tein receptor (VLDLR) contains 8 repeats, and the LDLR- 
related protein (LRP) carries clusters of 2, 8, 10, and 11 re- 
peats. Megalin or gp330 is the largest member of this family 
and contains 36 repeats in total. These proteins interact with a 
large number of unrelated ligands such as lipoproteins and 
proteinase-inhibitor complexes among several others (for re- 
cent reviews ee [1,2]). Homologues have been found through- 
out all species so far examined. In the laying hen, two sets of 
VLDLR and LRP-related proteins were identified which are 
specifically expressed in the developing oocyte and in somatic 
cells, respectively. The ovarian VLDLR (also termed OVR) is 
of particular interest as it can be rather easily prepared and is 
available in comparatively arge quantities [3 7]. A 39 kDa 
intracellular protein (receptor-associated protein or RAP) 
binds to most of the receptors of this protein family, although 
with different affinities, and thereby blocks the interaction 
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with the ligands [8 17]. Recently, we have shown that a minor 
receptor group of human rhinoviruses (HRVs), the main cau- 
sative agents of the common cold [18], bind to several mem- 
bers of the LDLR family including OVR [19,20]; however, the 
viruses are not replicated in cells other than human or primate 
[21]. 
Although negative charges on the surface of the receptor 
proteins are clearly involved in ligand recognition, the princi- 
ples underlying ligand discrimination and the exact site of 
attachment on the receptors have not been fully revealed. 
Moreover, knowledge of structures involved in virus-receptor 
interaction is highly desirable in view of blocking viral attach- 
ment to the host cell. For example, particular antibodies 
against intercellular adhesion molecule 1 (ICAM-1), the re- 
ceptor of the major group of human rhinoviruses, appear 
promising in antiviral therapy [22,23]. Similar studies with 
minor group viruses have mostly been hampered by the diffi- 
culty in raising antibodies blocking viral attachment by con- 
ventional immunization; only in some instances antibodies 
have been shown to interfere with ligand binding. However, 
the inhibition is usually weak since in general the antibodies 
bind to a site remote from the ligand binding site. For exam- 
ple, the monoclonal antibody IgG-C7 [24] was shown to be 
directed against he N-terminal repeat of LDLR which is not 
involved in ligand interaction [25]. We therefore investigated 
whether the screening of a library of phage-displayed anti- 
body fragments would lead to immunological reagents direct- 
ed towards the ligand binding site and thus prevent ligand 
attachment to the receptor. 
The display of repertoires of antibody fragments on the 
surface of filamentous bacteriophage, and the selection of 
antigen-binding phage [26,27] has provided means of obtain- 
ing antibodies without immunisation [28]. Thereby antibody 
repertoires are either derived from the rearranged V-genes of 
naive lymphocytes [29,30] or from V-gene segments rear- 
ranged in vitro [31 34]. We have used a large phage antibody 
repertoire derived from naive human lymphocytes to screen 
for antibody fragments against OVR, the oocyte-specific 
chicken very low-density lipoprotein receptor (VLDLR) [35]. 
In this communication we show that all single chain Fv 
antibodies elected at random from those isolated upon selec- 
tion for attachment to OVR bind to (or close to) the ligand 
binding site. As for all known ligands, the scFv receptor e- 
cognition is strictly Ca2+-dependent and is prevented by the 
receptor-associated protein (RAP). This indicates that these 
scFvs bind to a structural epitope which is also used by the 
various ligands. In contrast o a rabbit hyperimmune serum, 
they compete for binding of the minor group human rhino- 
virus HRV2 to OVR. These results indicate that the ligand 
binding site is a structure particularly prone to immune re- 
cognition; however, in vivo the high evolutionary conserva- 
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I ig. 1. Amino acid sequences of the selected scFvs as deduced from the cDNA sequence. DNA fragments encoding the heavy and light chains 
~f the 6 scFvs were amplified from bacterial colonies by polymerase chain reaction. Sequences were determined on an automatic DNA sequenc- 
e'" using fluorescent dideoxy-NTPs. CDR regions are shown in bold and are boxed. Only amino acids different from scFv7 are shown for the 
~ther scFvs. Since all light chains were identical, the five scFvs were divided into three groups based on sequence similarity of their heavy 
t aains. The sequence of scFv7 is from [35]. 
ton  of this site and/or the presence of various ligands in the 
[:lood prevent an efficient immune response to this epitope. 
2. Materials and methods 
? 1. Materials 
Crude membrane xtracts and purified OVR were prepared essen- 
t,ally as described in [35]. Purified human placental LRP was gener- 
ously provided by Dr. J. Gliemann, University of Aarhus, Denmark. 
I IRV2 was propagated and metabolically labelled with [35S]me- 
thionine in HeLa cells as described [36]. Rabbit hyperimmune 
l,~Gs, obtained from antiserum raised by injection of a rabbit with 
parified OVR [37], were kindly provided by J. Nimpf, University of 
X ienna, Austria. GST-RAP was expressed and purified as described 
[ 7]. 
; 2. Selection of antigen binding phage by library panning 
The phage antibody repertoire described previously and kindly pro- 
xded by Cambridge Antibody Technology (CAT), Cambridge, UK, 
~ as used for OVR-specific phage selection [35,38]. Briefly, repertoires 
of human heavy and light chain V-genes amplified from human lym- 
paocytes from tonsils were assembled to encode single chain Fv frag- 
ments. The assembled V-genes were cloned into the ampicillin-resist- 
aat phagemid pCANTAB6 (CAT, Cambridge, UK) to append a C- 
terminal hexahistidine (His) tag to allow for purification, and a myc 
tag to facilitate detection of the fragments. In the first round of selec- 
tion 10 la phage were panned for 2 h at room temperature using im- 
munotubes (Maxisorb, Nunc) coated with 10 gg/ml purified OVR in 
50 mM NaHCOa (pH 8.6). Four additional rounds were carried out 
in immunotubes coated with 5 I.tg/ml antigen as described [35]. 
2.3. Screening and sequencing of clones 
Phage were isolated from single ampicillin-resistant colonies of in- 
fected (suppressor) E. coli TG-1 using helper phage VCS-M13 (Stra- 
tagene), and the phage used to infect the (non-suppressor) E. coli 
HB2151. Single ampicillin-resistant colonies were used to inoculate 
200 lal of culture broth in microtiter plates, and the expression of 
soluble scFv fragments induced by addition of 1 mM IPTG to the 
cultures [35]. Bacteria were pelleted, and the supernatants containing 
scFv fragments were screened for binding to the antigen by ELISA 
using the anti-rnyc tag antibody 9El0 (Stratagene) and anti-mouse 
lgG conjugated with AP. Binding specificity was tested by comparing 
the signals obtained from plates coated with 100 lal of either 10 ~tg/ml 
OVR or of 100 ~tg/ml BSA. Soluble fragments resulting in an ELISA 
signal of at least 7 times higher for OVR than BSA were scored 
positive. Using specific primers [34] the encoded variable heavy and 
light chain regions were amplified via PCR from single colonies. The 
amplified DNA was subjected to automatic sequencing by the dideoxy 
method using the TAQ DyeDeoxy Terminator Cycle sequencing kit 
(Applied Biosystems Inc.) and the PCRHLINK primer [38] for the 
heavy chain region and FDSEQ1 [32] for the variable light chains. 
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2.4. Preparation of monoclonal reagents 
For further characterization f the scFv fragments, the infected 
HB2151 bacteria were grown in 1 litre of 2 × TY medium supplement- 
ed with 0.1% glucose and 100 ~tg/ml ampicillin and were induced 
overnight with 1 mM IPTG at 28°C. Bacteria were removed using a 
tangential filtration unit with 45 ~tm filters (Filtron) and the super- 
natant was precipitated with 50% (NH4)2SO4 overnight. The precipi- 
tate was collected by centrifugation and redissolved in 1/10 of the 
initial volume of PBS. Samples were affinity purified by immobilized 
metal chelate affinity chromatography (IMAC) using Ni-NTA (Dia- 
gen) as described [32]. The fractions eluted with 100 mM imidazole 
were analyzed by SDS-PAGE on 12.5% polyacrylamide gels under 
reducing conditions and were estimated to be greater than 90% 
pure. The concentration was determined spectrophotometrically s- 
suming A2s0 of 1.0=0.7 mg/ml [32]. Labelling of scFv7 with 125I 
was carried out using the chloramine T method with 0.5 mCi 125I 
(Amersham) per 70 Ixg of protein yielding a specific activity of 
1.5× 107 cpm//ag. The determination of binding kinetics by surface 
plasmon resonance (SPR) was carried out essentially as described [35]. 
2.5. Competition with GST-RAP 
1 lag/ml OVR (100 ~tl/well) was coated onto ELISA plates in 50 mM 
NaHCO3, pH 8.6 at 4°C. Plates were blocked with 2% milk powder in 
PBS for 1 h, washed with PBS and incubated for 1 h at room tem- 
perature with the different scFvs in PBS together with the amount of 
GST-RAP [17] indicated in the figures. Plates were washed 3 times 
with PBS, 0.2% Tween 20 and 3 times with PBS. ScFvs bound were 
detected using 9El0 at a dilution of 1:1000 followed by AP-conju- 
gated goat anti-mouse IgG; p-nitrophenyl-phosphate at 1 mg/ml in 10 
mM ethanolamine, 0.5 mM MgC12 (pH 9.5) was used as a substrate. 
Color development was measured at 405 nm using a BioRad ELISA 
reader after 1 b incubation at room temperature. 
2.6. Ca 2+ dependence of binding 
Approximately 1 ~tg OVR/5 mm gel width was run on a 12.5% 
SDS-polyacrylamide g l, transferred onto an Immobilon membrane 
and blocked in PBS containing 2% Tween 20. Binding of rabbit anti- 
OVR IgG [37] at 85/,tg/ml and of scFvs at 1 ~g/ml was assayed in the 
presence of either 2 mM CaC12 or 20 mM EDTA in PBS on individ- 
ual strips cut from the membrane. Rabbit antibodies were detected 
with AP-conjugated anti-rabbit IgG (Promega), scFvs with 9El0 fol- 
lowed by AP-conjugated goat anti-mouse IgG employing BCIP and 
NBT as substrates. 
2. Z Competition assays 
Competition assays were carried out using ELISA plates coated 
with 1 ~tg/ml OVR or human LRP at 100 ial/well, in 50 mM NaHCO3, 
pH 8.6 at 4°C overnight. Plates were blocked with 2% milk powder in 
PBS for 1 h, washed with PBS and incubated with 13 000 cpm/well 
(about 1 ng) [12'~I]scFv7 together with the various unlabelled scFvs in 
PBS for 1 h at room temperature at the concentrations indicated in 
the figures. The plates were washed 3 times with PBS, 0,2% Tween 20 
and 3 times with PBS. Wells were cut, and bound radioactivity was 
determined using an auto-gamma-counter Cobra II (Packard). In or- 
der to test the competition of scFvs for [32S]HRV2 binding to OVR, 
the antibodies were present at 200/.tg/ml, and the virus at 30 000 cpm/ 
well. The assay was essentially done as described above. 
3, Results 
3.1. Binding characteristics of  the selected scFvs 
After selection of the repertoire of phage-displayed scFv 
fragments for binding to OVR, 36 individual clones were cho- 
sen at random for further analysis. From these, 27 scored 
positive in an ELISA-based assay [35]. In order to determine 
the redundancy of these clones, the regions encoding the 
heavy and light chain CDRs were amplified by PCR and 
the cDNA sequences were determined; from these 27 clones, 
6 (including the previously described scFv7 [35]) were found 
to have different sequences in their heavy chains, whereas all 
had the same light chain sequence. Based on comparisons 
with the repertoire of human variable genes these scFvs 
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Fig. 2. Competition of GST-RAP for binding of scFvs to OVR. 1 
gg/ml (100 gl/well) OVR was coated onto microtiter plates. After 
blocking, the wells were incubated with the various scFvs at 200 lag/ 
ml in the presence of GST-RAP at the concentrations indicated. 
After washing, bound antibody fragments were detected with 9El0 
and AP-conjugated antiserum and color intensity was measured 
with a microplate reader. Maximum binding (100%) was determined 
for each scFv in the absence of competitor and was between 0.35 
A405 (scFv7) and 0.15 A4(15 (scFv8). Background was 0.1 A40 s using 
the irrelevant scFv D1.3; it was subtracted from all values. The 
mean of two independent experiments i  shown. Differences between 
the duplicates were less than 10%. 
were classified as belonging to three antibody germline fam- 
ilies: DP-7 (VH1) for scFv6 and scFv7 [35], DP-49 (VH3) for 
scFv8, and DP-25 (VH1) for scFvs 19, 21, and 27 [39] (Fig. 1). 
Note that those clones with identical CDR sequences are 
slightly different in their framework regions. 
Soluble fragments of each clone were then prepared and 
affinity purified on N i -NTA columns using the His tag se- 
quence located at the C-terminus of the protein. These frag- 
ments were tested for affinity toward OVR and LRP  in West- 
ern blots. Receptors in crude membrane xtracts from hen 
ovaries were separated on 12.5% SDS-PAGE and transferred 
onto Immobi lon membranes. Incubation with the respective 
scFvs followed by immunodetect ion with AP-conjugated anti- 
sera resulted in a single band corresponding to OVR;  in a 
similar experiment purified LRP was run on a 7.5% polyacryl- 
amide gel and transferred to Immobilon. Western blotting 
revealed that only scFv6 and scFv7 cross-reacted with human 
LRP whereas the remaining 4 antibody fragments did not 
bind to LRP (data not shown). The irrelevant scFv D1.3 
(which recognizes hen egg lysozyme [26]) was used as a con- 
trol and showed no reaction in either blot. 
3.2. Competition with RAP  
RAP, a 39 kDa intracellular protein that copurifies with 
LRP, is known to compete for binding of all l igands to 
LRP and VLDLR [13,17,19,40,41]. To determine whether 
RAP  would also interfere with attachment of the scFvs to 
OVR, the receptor was coated onto ELISA plates and binding 
of the antibody fragments was assayed in the presence of 
various concentrations of recombinant GST-RAP.  The pres- 
ence of GST-RAP in the incubation resulted in a concentra- 
tion dependent decrease of binding of the scFvs to OVR. 
However, as seen in Fig. 2, the concentration of GST-RAP 
required to inhibit binding of the individual scFvs to OVR 
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was different: whereas the binding of scFv8 was completely 
abolished at 100 ~tg/ml GST-RAP, the presence of GST-RAP 
at 1 mg/ml reduced binding of scFv7 to about only 75%. 
l~ahibition of the other scFvs by GST-RAP was found to be 
i,atermediate. Closer inspection of the data revealed that those 
scFvs grouped together by sequence similarity were also simi- 
1.tr in their binding properties. ScFv6 and scFv7 were both 
nly inhibited at high concentrations of RAP, while scFvl9, 
." 1, and 27, belonging to another group, required moderate 
~,mounts of GST-RAP for competition. Finally, scFv8 was 
~ost easily replaced by GST-RAP. 
. 3. Ca 2+ dependence o f  binding 
Members of the LDL receptor family require Ca 2+ ions for 
~e  stabilization of the ligand binding site [42~4]. Therefore, 
l ie  influence of Ca 2+ ions on the binding of scFvs to OVR 
~'as tested on a Western blot obtained from an oocyte meta- 
l ?ane extract. As has been shown for scFv7 [35], binding of 
~Jll other scFvs to OVR was also strictly dependent on the 
I resence of Ca 2+ ions and was abolished by addition of excess 
1 DTA. This is in sharp contrast to the IgG fractions of the 
~ tbbit hyperimmune serum raised against OVR which bound 
I ) the receptor egardless of the absence or presence of EDTA 
uring incubation (Fig. 3). 
. 4. Competition with HR V2 Jbr binding to 0 VR and to LRP  
Competition of RAP for binding of all scFvs to OVR 
s.rongly suggests that these ligands recognise the same, or at 
1,:ast an overlapping epitope on the receptor surface. The 
s,Fvs were thus assayed for their ability to compete for bind- 
i lg of another ligand of the LDL receptor family, human 
1 linovirus serotype 2 (HRV2). This picornavirus belongs to 
l ie  minor rhinovirus receptor group and thus binds to the 
l DL receptor and to LRP [19]. Although HRVs are not rep- 
1 cated in chicken cells, they also bind to OVR [20]. These 
iruses can thus be considered universal ligands of the 
l DLR family since other ligands are less promiscuous as 
1 ley bind with rather different affinities to different receptors 
[ ~;,45,46]. As shown in Fig. 4A, the scFvs decreased binding of 
: S-labeled HRV2 to OVR immobilized in microtiter plates to 
I I I  I I  II I I  I I  II I 
+ - + - + - + - + - + -+ - Ca ++ 
I I 
~i~ii ~
I I OVR 
1 ig. 3. Binding of all scFvs to OVR is Ca2+-dependent. Purified 
(WR was run on a 12.5% SDS-polyacrylamide g l and electrophore- 
t~cally transferred onto an Immobilon membrane. Individual strips 
t~om the membrane were incubated either with rabbit anti-OVR 
I~G (OVR-AS) or with the scFvs as indicated in the presence of 2 
nM CaC12 or of 20 mM EDTA. The blot was developed with 9El0 
a~ad AP-conjugated goat anti-mouse IgG, or AP-conjugated anti- 
r:tbbit IgG, for scFvs and the rabbit hyperimmune serum, respec- 
tively, using BCIP and NBT as substrates. 
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Fig. 4. Competition of HRV binding to OVR (A) and LRP (B) by 
scFvs. OVR and LRP were immobilized to microtiter wells as in 
Fig. 2 and incubated with 30000 cpm/well [:~SS]HRV2 in the pres- 
ence of 200 gg/ml of the scFvs or of 5 mg/ml of the IgG fraction 
of the hyperimmune serum against OVR (OVR-AS). After washing, 
the wells were cut and bound radioactivity was determined by liquid 
scintillation counting. Maximal binding (100%) was between 1000 
and 2000 cpm to OVR and between 700 and 1000 cpm to LRP. 
Background binding to wells coated with BSA was 30 cpm. No re- 
duction in binding was seen with the control scFv DI.3. The mean 
of at least two independent experiments i  shown. 
various degrees. At 200 gg/ml scFv6, 7, 21, and 27 reduced 
HRV2 binding to between 40% and 10%, while the other three 
scFvs decreased HRV2 binding to between 70% and 85%. 
As expected from earlier experiments which had demon- 
strated binding of scFv7 to human LRP and inhibition of 
virus infection of human fibroblasts deficient in LDLR but 
expressing LRP [35], scFv7, scFv6, and scFv21 also decreased 
HRV2 binding to immobilized LRP to 10, 50, and 60%, re- 
spectively when added at 200 pg/ml. As anticipated from the 
lack of cross-reactivity with LRP in Western blots (see above), 
scFv 8, 19, 21, and 27 had no detectable influence on HRV2 
binding to this receptor (Fig. 4B). Note, however, that binding 
of these scFvs to LRP could be demonstrated in surface plas- 
mon resonance experiments (see below). The control scFv 
DI.3 used at the same concentration did not interfere with 
HRV2 binding. 
In order to examine whether the differences in specificity for 
OVR or LRP in ligand competition were only a matter of 
different affinities of the individual scFvs for the respective 
receptor proteins, the affinity constants were determined by 
plasmon surface resonance technology. Purified OVR and 
LRP were immobilized on CM5 sensor chips as described 
previously [35]. Purified scFvs were applied at three different 
concentrations with each measurement being carried out three 
times. Affinity constants were calculated from the on- and off- 
rates and are summarized in Table 1A for OVR and in Table 
1B for LRP. ScFv6 showed a dissociation constant in the 
nanomolar ange for OVR and LRP and is thus very similar 
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Fig. 5. Cross-competition f scFv binding to OVR. OVR was im- 
mobilized to microtiter wells as in Fig. 2 and incubated with 13 000 
cpm/well (1 ng/100 ktl) of 125I-labelled scFv7 in the presence of in- 
creasing concentrations of unlabelled scFvs. Bound radioactivity 
was determined from wells cut out with a scalpel in a Packard Co- 
bra II 7-counter. 
to scFv7 [35]; scFvl9, 21 and 27 showed slightly lower affinity 
to both receptors. As expected from the binding data on 
Western blots and from competition with GST-RAP, the af- 
finity of scFv8 for OVR as well as for LRP was found to be 
about three times less than that of scFv6 and scFv7. 
3.5. Cross-competition of scFv 
Since all scFvs had been found to compete for HRV2 bind- 
ing to OVR, although to various degrees, we wanted to de- 
termine whether this competition was the result of binding to 
the same epitope or to epitopes in the close vicinity. As scFv7 
competes most strongly with HRV2, this antibody fragment 
was labelled with 1251 and its binding to OVR was monitored 
in the presence of the other scFvs at various concentrations 
(Fig. 5). Unlabelled scFv7 and scFv6 reduced binding of 1251- 
labelled scFv7 in a concentration-dependent manner with re- 
duction to background values at 50 lag/ml. ScFv8, 19, 21, and 
27 showed no significant inhibition of the interaction between 
scFv7 and OVR, even at 200 ktg/ml (Fig. 5). 
4. Discussion 
Antibodies that block the interaction of multiple ligands to 
the LDL receptor family should help to narrow down sites 
involved in ligand binding and to understand the principles 
underlying differences in affinity of various ligands for each 
particular eceptor. Moreover, as has been demonstrated for 
major receptor group rhinoviruses, antibodies against he re- 
ceptor can be used to block infection [22]. In this case the only 
portal of entry is the intercellular adhesion molecule 1 
(ICAM-1) whereas minor group viruses bind to several 
although closely related receptors. Therefore, antibodies 
with wide cross-reactivity towards members of the LDLR 
family could possibly be used to block the attachment of 
minor group human rhinoviruses to their natural host cells 
and thus inhibit infection. 
Although antisera and monoclonal antibodies have been 
obtained against several members of the LDLR family, 
none have unequivocally been demonstrated to bind to the 
ligand binding site, although inhibition of ligand uptake 
through down-regulation of the receptors was frequently ob- 
served. For instance, the monoclonal antibody IgG-C7 inter- 
feres with the interaction of LDL and apo-E-rich lipoproteins, 
with the LDL receptor, but only to a moderate xtent [24]. 
Since this antibody binds to the amino-terminal cysteine-rich 
repeat - which is not required for ligand binding [25] - it is 
not particularly surprising that it inhibits viral attachment 
only moderately [19]. The difficulty in obtaining antibodies 
with the desired properties by conventional means may be 
due to the conserved nature of the binding epitopes on the 
receptors between different species, or the presence of ligands 
in the serum of the animal tO be immunised rendering the 
binding site inaccessible. We therefore mployed the technique 
of antibody display phage libraries for the production of 
scFvs with affinity for the chicken OVR. This receptor was 
chosen because of the ease of purification and the compara- 
tively large amount being expressed in the growing oocyte. 
HRVs strongly bind to this protein although virus is not rep- 
licated in chicken cells [20]. A repertoire consisting of 109 
different clones was screened for binding to OVR. We suc- 
ceeded in the isolation of six different scFvs which were all 
found to bind strongly to OVR. All of these antibody frag- 
ments competed for HRV binding to this receptor, but to 
different extents. As expected from results with antisera or 
monoclonal antibodies raised against LDLR or LRP 
[24,47,48], a hyperimmune serum obtained by immunization 
with OVR strongly bound to its antigen as seen by Western 
blotting but failed to show any influence on HRV2 binding to 
OVR (Fig. 4). 
Cross-competition experiments showed that at least scFv6 
Table 1 
Affinity constants for scFv binding to OVR (A) and LRP (B) 
Kon Koff K~ff Conc 
(M -1 s-1))<10 4 (s-1))<10 -3 (M-1)×10 7 (M)×10 -6 
A 
scFv6 10 0.5 20 0.45-1 
scFv7 8 0.3 26.6 0.1 -2 
scFv8 6 1.2 5 0.334).5 
scFvl9 15 1.1 13.6 0.094).13 
scFv21 7 0.5 14 0.134).4 
scFv27 15 1 15 0.09-0.27 
B 
scFv6 2.5 0.27 9 0.5 -1.5 
scFv7 3 0.3 10 0.4 -2 
scFv8 9 2.5 3.6 0.3 1 
scFvl9 5 0.75 6.7 0.2 4).4 
scFv21 4 0.6 6.7 0.1 4).5 
scFv27 8 1 8 0.2 4).4 
35 ~tl of pure scFv preparations at the concentrations i dicated were 
passed over a sensorchip surface to which 1200 resonance units (RU) 
of OVR (A) and of LRP (B) had been coupled. On/off rates, affinity 
constants and the range of concentrations used for the determinations 
are shown. Constants are the mean values of determinations at three 
different concentrations. All measurements were carried out in tripli- 
cate, Values for scFv7 were taken from [35]. The irrelevant scFv D1.3 
passed over both surfaces showed neither binding to OVR nor to 
LRP. 
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and scFv7 bind to the same epitope on the receptor surface. 
However, the remaining scFvs failed to compete for the site 
recognized by scFv6 and scFv7 (Fig. 5). Since all of the scFvs 
inhibit binding of HRV2 to OVR they all must bind to (or 
close to) the viral attachment site. The viral binding site is 
highly conserved within the LDLR family since minor group 
HRVs bind to LDLR, to LRP, to OVR, and to megalin (un- 
l~ublished). Upon Western blotting only scFv6 and 7 recog- 
l ized LRP whereas cFv8, 19, 21, and 27 did not, again in- 
¢icating that the former antibodies attach to the most 
conserved structure within these receptors. The site in LRP 
¢orresponding to that site in OVR which is recognized by 
~.:Fvl9, 21, and 27 might be in a somewhat altered conforma- 
1 on after SDS gel electrophoresis since determination of the 
ffinity constants by surface plasmon resonance revealed that 
lese antibodies had only a slightly lower affinity than scFv6 
nd 7; scFv8 binds with about four-fold lower affinity. These 
,ata, together with the differences in ligand competition and 
'~ae data from the cross-competition, suggest hat scFvl9, 21, 
~nd 27 bind to an epitope different from that recognized by 
~,~Fv6 and 7. Nevertheless both epitopes must be close to (or 
verlapping with) each other since all antibodies are competed 
~,y RAP and all antibodies prevent HRV2 binding to OVR. 
Recently, Horn and coworkers [49] have selected an anti- 
~,ody fragment blocking the binding of pro-urokinase and 
xokinase-plasminogen-activator-inhibitor-1 c mplexes to 
!,RP from a phage-displayed Fab library. However, the phage 
brary  was made from mRNA recovered from the lympho- 
. ytes from a mouse which had been immunized with the anti- 
.=en. Moreover, selection was biased towards antibodies bind- 
ag  to a structural epitope by eluting phage during the 
!,anning procedure by EDTA. In our case a library obtained 
~rom naive human lymphocytes was used and no selection for 
: ntibodies binding to a structural epitope was made. Never- 
heless, binding of all scFvs isolated was Ca 2+-dependent (Fig. 
), they were displaced from the receptor by RAP (Fig. 2), 
nd  they competed with HRV2 for binding to OVR (Fig. 4). 
In the first two respects, the antibody fragments behave very 
• imilarly to all known ligands of the LDL receptor family. 
7hey clearly recognize sites which are not immunodominant 
n vivo indicating that they might be hidden for the immune 
• ystem or that an immune reaction against hese sites is spe- 
,ifically suppressed. In addition to the previous finding that 
]~hage display technology ields antibodies which are not ob- 
l ained by conventional means our  results indicate that 
• trongly exposed sites in evolutionarily highly conserved pro- 
~eins might not be seen by the immune system but are per- 
ectly targeted by antibodies which are not subject to the 
election mechanisms operating in vivo. It will be of interest 
o investigate the basis for the strong (in vitro) immunogenic 
~ehavior of these particular sites in OVR. 
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